Stay updated with breaking news from Phase 3. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results from EoE KIDS showed 68% of patients on a higher dose of dupilumab and 58% of patients on a lower dose achieved significant histological disease remission.
Relmada Therapeutics, Inc. (RLMD) saw a 6% increase in share value on Monday. This was due to the announcement of efficacy and safety results from their Phase 3 study (Study REL-1017-310) of REL-1017 in patients with Major Depressive Disorder (MDD).
The discontinuation of LIMT-2 was announced after 4 patients experienced hepatobiliary events resulting in liver decompensation during the phase 3 study of peginterferon lambda for HDV.
Risankizumab outperformed ustekinumab in rates of clinical remission at week 24 and rates of endoscopic remission at week 48, meeting both primary endpoints of the phase 3 trial.
An oral treatment, developed by the U.S. company Crinetics Pharmaceuticals, Inc., has shown promise as an alternative to injected therapies for tackling the rare disease acromegaly in a phase 3 trial.